drugset / Trial / NCT06984146
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Phase 2
Recruiting
54 enrolled
National Medical Research Radiological Centre of the Ministry of Health of Russia
NaSingle-groupOpen-labelTreatment
Summary
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
Timeline
- Start
- 2025-04-15
- Primary completion
- 2028-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dacarbazine | Small molecule | 375 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 40 mg | Intravenous |
| Subject | Vinblastine | Small molecule | 6 mg/m2 | — |